ADMA BiologicsADMA -0.54%64 PB Ratio is 5.45 as of Jul. 09, 2026, which is 6% below its 10-year median of 5.79. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.04 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 1,226 Biotechnology companies, ADMA Biologics ranks worse than 72.27% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-09), ADMA Biologics's share price is $9.16. ADMA Biologics's Book Value per Share for the quarter that ended in Mar. 2026 was $1.68. Hence, ADMA Biologics's PB Ratio of today is 5.45.
The historical rank and industry rank for ADMA Biologics's PB Ratio or its related term are showing as below:
ADMA'
s PB Ratio Range Over the Past 10 Years
Min: 1.41 Med: 5.79 Max: 25.82
Current: 5.45
During the past 13 years, ADMA Biologics's highest PB Ratio was 25.82. The lowest was 1.41. And the median was 5.79.
ADMA's PB Ratio is ranked worse than 72.27% of 1226
companies
in the Biotechnology industry
Industry Median: 2.89
vs ADMA: 5.45
During the past 12 months, ADMA Biologics's average Book Value Per Share Growth Rate was 7.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 43.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 19.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ADMA Biologics was 77.00% per year. The lowest was -57.80% per year. And the median was 15.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ADMA Biologics PB Ratio Related Terms
ADMA Biologics PB Ratio Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ADMA Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ADMA Biologics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ADMA Biologics (ADMA) has a PB Ratio of 5.45 as of Jul. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ADMA Biologics and its competitors. This is near median its historical median of 5.79. Over the past decade, ADMA Biologics' PB Ratio has ranged from 1.41 to 25.82. According to the industry distribution chart, ADMA Biologics ranks #886 out of 1226 companies in the Biotechnology industry, placing it in the top 72.3%.
Is ADMA Biologics' PB Ratio too high?
ADMA Biologics' current PB Ratio of 5.45 is near median its 10-year median of 5.79. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 25.82. The Biotechnology industry median PB Ratio is 2.89. ADMA Biologics' value of 5.45 is 88.6% above this industry median. Based on the distribution chart, ADMA Biologics ranks #886 out of 1226 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' PB Ratio compare to ZLAB and HRMY?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #886 out of 1226 companies for PB Ratio. This places ADMA Biologics in the lower half of its industry. The industry median PB Ratio is 2.89. ADMA Biologics' value of 5.45 is 88.6% above this benchmark. Historically, ADMA Biologics' own PB Ratio has ranged from 1.41 to 25.82 over the past decade. While the company's 10-year median is 5.79 vs. the industry median of 2.89, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,226 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current PB Ratio of 5.45 is 88.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current PB Ratio is 5.45, which is near median its own 10-year median of 5.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.04, compared to a current price of $9.16 — trading 49.2% below its estimated fair value. The current PB Ratio is 5.45, which is near median its 10-year median of 5.79 and 88.6% above the Biotechnology industry median of 2.89. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current PB Ratio is 5.45 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.16 is trading 49.2% below its estimated GF Value™ of $18.04.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
PB Ratio: 5.45 (near median its 10-year median of 5.79)
GF Value™: $18.04 vs. price of $9.16 (49.2% below fair value)
Industry Position: 88.6% above the Biotechnology median (#886 of 1226)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
